Innovation in Mexico - part 2

Last month JackLeckerman had the privilege to welcome Sonia Mayra Pérez Tapia (General Director - UDIBI) who took part in Biosimilars LatAm - Mexico 2022 hosted in Cancun. Her session of Innovation in Mexico was all about important insights about #biosimilars in Mexico.

If you missed the first part about Biosimilars in Mexico, head out to this article first.

Biosimilars in UDIBI (part 2)

The Unit for Research and Development in Biotherapeutics UDIBI , is located at the National School of Biological Sciences of the National Polytechnic Institute. UDIBI is a highly specialized National Laboratory and Authorized Third Party Laboratory by COFEPRIS which focuses on research, innovation, and development, of biotherapeutics, as well as, the development of analytical services for the biopharmaceutical products at different development stages. UDIBI offers its capabilities to support the development of projects of the national and international pharmaceutical industry, as well as for the national academia.

We are a third-party laboratory authorized by COFEPRIS as Pre-clinical Unit to conduct biosimilarity tests of biotechnological medicines (TA-30-20).

Innovation Platform UDIBI

Why do we need to develop our own antibodies?

• To be self-sufficient in technology 
• To cover our national need for medicines at affordable costs for the government and patients
• To own the intellectual property
• To create scientific and technological foundations for a fast response to health emergencies.

Innovative antibodies with complete intellectual authorship

The Process

The Value

• Close relationship with the Mexican regulatory authority (COFEPRIS) level 4, it is part of the ICH, which makes it part of an agency with a high level of demand according to the WHO
• UDIBI is part of an interinstitutional network. Also, has access to a wide infrastructure that allows accelerated developments
• We are able to work along with other local and foreign institutions to provide a fast response to health emergencies
• Competitive prices due to reduced operating costs and openness in the Latin American market

*All the information in this article was collected during Biosimilars LatAm - Mexico (November 2022) and is a property of Sonia Mayra Pérez Tapia (General Director - UDIBI)